Breakthroughs in Stem Cell Based Treatment of Heart Disease – The Connecticut College Voice
Posted: November 24, 2020 at 9:57 pm
Photo Courtesy of Unsplash.
In the United States alone, one person dies every 36 seconds from cardiovascular disease. Globally, it is also the leading cause of death, claiming over 17 million lives each year. In cases of severe illness, heart transplants have shown great promise in increasing the life expectancy of patients with heart disease. About 75% of heart transplant recipients survive for 5 more years and about 56% survive for 10 more years. However, the average wait times for heart transplants are long, often exceeding 6 months, and some patients simply cannot afford to wait that long.
Therefore, scientists tend to refer to other modes of treatment which rely on managing chronic symptoms, such as hypertension (high blood pressure), diabetes mellitus, obesity, and high cholesterol. This approach, however, does not address the root cause of the problem, which is impaired heart functioning. Since heart cells do not have a mechanism to replace damaged tissue, scientists have become increasingly excited about the possibility of repairing or replacing damaged heart tissue using stem cells (unique cells that have the ability to divide for an extended period of time and differentiate into specialized cells, such as cardiac cells or nerve cells).
Regenerative medicine has been a topic of excitement among researchers for decades. In 1999, Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, was the first to implant lab-grown organs into several patients between 4 and 19 years old. In his method, he obtained bladder cells from the children and coaxed those cells into dividing on a scaffold (a structure that mimics the normal organ). The engineered bladders functioned normally and no ill effects were reported. Pretty much I was able to live a normal life after, said Luke, one of Atalas patients.
More recently, Yoshiki Sawa, a professor of cardiovascular surgery at the University of Osakas medical school, and his team of Japanese researchers successfully transplanted lab-grown cardiac muscles into a human patient. The researchers first extracted adult stem cells from the patients blood or skin and genetically reprogrammed them into induced pluripotent stem (iPS) cells. They were then coaxed into 0.1-millimeter-thick sheets of cardiac tissue and grafted onto the diseased human hearts. According to Sawa, the cells do not seem to integrate into the heart tissue but rather release growth factors (proteins) that help regenerate blood vessels in the damaged muscle tissue and improve cardiac function. The team has conducted an operation on a patient in January 2020, marking the worlds first transplant of cardiac muscle cells.
The United States is also home to major breakthroughs in regenerative medicine. For decades, scientists have utilized embryonic stem cells to engineer heart muscle cells that are able to maintain synchronous breathing in a dish for hours. Despite this major feat, the creation of a working heart called for a more sophisticated technique. Doris Taylor, director of regenerative medicine research at the Texas Heart Institute (THI), has grown in her lab over 100 ghost hearts using protein scaffolds. She creates these scaffolds by first obtaining an animal heart and then decellularizing it by pumping a detergent through its blood vessels to strip away lipids, DNA, soluble proteins, sugars and almost all the other cellular material from the heart, leaving only a pale mesh of collagen, laminins, and the extracellular matrix. This heart does not necessarily have to be a human heart. She often finds pig hearts to be promising tissue because of their considerable safety and unlimited supply. She then recellularizes the heart by injecting it with millions of stem cells and attaching it to artificial lungs and a blood pump. Although her technique has only been used so far for growing animal hearts, she believes that it will eventually be used to create human heart transplants, thus, revolutionizing cardiovascular surgery and putting an end to organ shortage and anti-rejection drugs.
These groundbreaking results in regenerative medicine altogether have taken years of painstaking research to achieve. Taylor believes that her research is exceptionally close to building a working, human-sized heart, and Sawa says that his technique of grafting healthy cardiac muscle sheets onto the patients diseased heart tissue has already helped one of his patients move out of intensive care in just a few days. As the researchers gain more knowledge and get closer to the solution, however, they encounter more challenging obstacles. Sawa, for instance, has found that grafted cells do not always beat in synchrony. Researchers are also split on how these grafts work. On the other hand, investigating the best way to deliver cells still remains a challenge in Taylors research.
Stem cell research in tissue engineering could save millions of lives around the world; therefore, Taylor believes that a coordinated approach among the researchers, clinicians, industry, regulatory bodies and, finally, society should be invigorated to catapult the field forward. For instance, the Twenty-first Century Cures Act can help advance her work by facilitating cooperation among experts and regulatory bodies, providing for accelerated approvals for therapeutic tools in regenerative medicine, and improving the regulation of biologics products. She also maintains that tissue engineering efforts remain poorly funded and believes that more resources must be allocated before her studies can come to life. There is a lot of dependence on societal benevolence, she said. In an interview with RedMedNet, she also said that intense collaboration on a national and an international level is crucial and should be a priority, even though it could be challenging due to scheduling issues and differences in time zones.
(Visited 13 times, 13 visits today)
See the rest here:
Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice
- Worldwide Industry for Biopreservation to 2026 - Key Drivers, Restraints and Opportunities - Yahoo Finance - January 5th, 2021
- Vape Flavorings Are Cardiotoxic and Can Damage the Heart - SciTechDaily - December 28th, 2020
- Outlook on the Biopreservation Global Market to 2026 - Profiling Avantor, BioLife Solutions and ThermoGenesis Among Others - GlobeNewswire - December 26th, 2020
- UC Davis researchers find a way to help stem cells work ... - December 17th, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 17th, 2020
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 17th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 17th, 2020
- Network of Genes Involved in Congenital Heart Disease Identified - Technology Networks - December 17th, 2020
- Industry News: Hamamatsu Photonics UK Ltd and the Medical Technologies Innovation Facility enter into a partnership agreement - SelectScience - December 17th, 2020
- Osteoporosis treatments could be on the way after scientists identify aging gene - iNews - November 30th, 2020
- Global Myocardial Infarction Drug Market to have sustainable growth over the forecast period 2020-2028| Leading Players BioCardia, Inc., Laboratoires... - November 30th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 24th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 24th, 2020
- 3D Cardiac Mapping Systems Market Competitive Landscape Analysis with Forecast by 2028 - The Haitian-Caribbean News Network - November 24th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 18th, 2020
- Mimicking the early development of the heart - Tech Explorist - November 18th, 2020
- Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.com - Business Wire - November 18th, 2020
- UPDATED: Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? - Endpoints News - November 18th, 2020
- Can Hearts Repair Themselves Via Stem Cells - The Niche - November 13th, 2020
- Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs ... - November 13th, 2020
- Global Autologous Stem Cell Based Therapies Market 2020 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2025 - The... - November 13th, 2020
- The Amniotic Fluid Stem Cell Therapy market to be in conjunction to growth from 2018 to 2026 - PRnews Leader - November 13th, 2020
- BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights - GlobeNewswire - November 13th, 2020
- Exploring Genetic Variation and COVID-19 Clinical Variability - Technology Networks - November 13th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 10th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 10th, 2020
- Global Progenitor Cell Product Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2026 - Zenit News - November 10th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients... - November 10th, 2020
- Advancement: Know the Rapid Growth Factors of Biopreservation Market| Stay Up-To-Date With Emerging - PharmiWeb.com - November 10th, 2020
- Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader - November 4th, 2020
- California Prop 14 would keep taxpayer funding of stem cell therapy research, which can change lives: Meet the Langenhop kids - AZCentral.com - November 4th, 2020
- Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition - Business Wire - November 4th, 2020
- Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over2017 2025 - Royal Sutton News - November 4th, 2020
- Autologous Stem Cell Based Therapies Market to Witness Increase in Revenues by 2020-2026 - PRnews Leader - November 3rd, 2020
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire - November 3rd, 2020
- Ready To Use Autologous Stem Cell Based Therapies Market Industry Analysis, Trend and Growth, 2020-2020 - Royal Sutton News - November 1st, 2020
- Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire - November 1st, 2020
- Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser - November 1st, 2020
- The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients - DocWire News - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Stem Cell Assay Market expected to Witness a Sustainable Growth over 2025 - TechnoWeekly - October 23rd, 2020
- Exosome Therapeutic Market 2020-2026 Demand Analysis and Projected Huge Growth by Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 23rd, 2020
- Stem Cell Assay Market In-Depth Analysis & Forecast 2017-2025 - The Think Curiouser - October 22nd, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 22nd, 2020
- Exosome Therapeutic Market 2020-2026 to Witness Excellent Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 22nd, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 16th, 2020
- Global Cell Based Assay & High Content Screening Markets to 2024: Updated Report - Understand Growth Expectations and the Potential Market Size -... - October 16th, 2020
- Merck Presents Three-Year Survival Data for KEYTRUDA (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational... - October 16th, 2020
- Preclinical Study Shows Improvement In Recovery From Heart Attack With Exosomes - Anti Aging News - October 10th, 2020
- Autologous Stem Cell Based Therapies Market Size, Business Revenue Forecast, Leading Competitors And Growth Trends 2026| Regeneus, Mesoblast,... - October 10th, 2020
- Recording thousands of nerve cell impulses at high resolution - Newswise - October 4th, 2020
- Wisconsin Medicine Livestream: The future of medicine - Wisbusiness.com - October 2nd, 2020
- Measuring chips amplify and record nerve cells - Futurity: Research News - October 2nd, 2020
- Recording thousands of nerve cell impulses at high resolution - ScienceDaily - Up News Info - October 2nd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 30th, 2020
- Heart attack patches may save lives in US and beyond - Galveston County Daily News - September 30th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2025 Global Briefing, Growth Analysis And Opportunities Outlook | Major Giants ... - September 30th, 2020
- Exosome Therapeutic Market Latest Industry Size, Growth, Share, Emerging Demands, and Competitive Landscape || Major Gaints Jazz Pharmaceuticals,... - September 30th, 2020
- James T. Willerson, Revered Clinician, Editor, and Mentor, Dies at 81 - TCTMD - September 22nd, 2020
- Researchers Discover a Way To Create Induced Tropoblast Stem Cells - Technology Networks - September 18th, 2020
- What Is Covid-19 Doing to Our Hearts? - The New Republic - September 18th, 2020
- Astellas and Seattle Genetics Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated... - September 18th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - BioSpace - September 14th, 2020
- David Shavelle, MD, Named Medical Director of Adult Cardiology for the MemorialCare Heart & Vascular Institute at Long Beach Medical Center -... - September 14th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 14th, 2020
- How the coronavirus causes 'carnage' in the heart - The Daily Briefing - September 9th, 2020
- Innovative treatments for heart failure - Open Access Government - September 9th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Scope And Price Analysis 2020 | Major Giants Fibrocell, Genesis Biopharma, Georgia... - September 9th, 2020
- Microengineered 3D pulmonary interstitial mimetics highlight a critical role for matrix degradation in myofibroblast differentiation - Science... - September 9th, 2020
- COVID-19 Drug Discovery and Development Why Diverse Strategies Are Critical - Technology Networks - September 9th, 2020
- Much-loved son Joe Brown saved three lives after tragic death at just 29 - Birmingham Live - September 9th, 2020
- Market Growth of Global Stem Cells to Remain Sluggish through 2020 2030 - The News Brok - September 4th, 2020
- Global and Asia Pacific Progenitor Cell Product Market to Witness Huge Growth by 2027 Major Manufacturers included in report NeuroNova AB, StemCells,... - September 4th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2025 | Major Giants Fibrocell, Genesis Biopharma, Georgia Health Sciences... - August 29th, 2020
- Keio University gets OK for iPS-based heart cell transplant plan - The Japan Times - August 29th, 2020
- Scientists grow the first functioning mini human heart model - MSUToday - August 22nd, 2020
- First lab-made 'mini-hearts' mimic the real thing - Futurity: Research News - August 22nd, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With... - August 19th, 2020
- Exosome Therapeutic Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 -... - August 19th, 2020
- Stem Cell Therapy Market Landscape Assessment By Type and Analysis Current Trends by Forecast To 2025 - The Daily Chronicle - August 17th, 2020